Shares of Radius Health, Inc. (NASDAQ:RDUS) have earned an average recommendation of “Hold” from the eleven ratings firms that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $57.80.

A number of brokerages recently commented on RDUS. Jefferies Group LLC reaffirmed a “hold” rating and issued a $38.00 target price (up from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $45.00 target price on shares of Radius Health in a research report on Friday, October 6th. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Maxim Group reissued a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Finally, BidaskClub lowered Radius Health from a “hold” rating to a “sell” rating in a report on Friday, August 11th.

Shares of Radius Health (NASDAQ:RDUS) traded down 0.62% during trading on Wednesday, hitting $36.98. The stock had a trading volume of 127,774 shares. Radius Health has a one year low of $31.58 and a one year high of $55.97. The stock’s market capitalization is $1.61 billion. The stock has a 50 day moving average price of $36.69 and a 200-day moving average price of $38.73.

Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.23). The company had revenue of $0.98 million during the quarter, compared to analyst estimates of $1.96 million. During the same period last year, the firm earned ($1.01) earnings per share. On average, equities research analysts predict that Radius Health will post ($5.55) earnings per share for the current year.

In other Radius Health news, major shareholder Growth N. V. Biotech bought 50,000 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were purchased at an average price of $36.75 per share, for a total transaction of $1,837,500.00. Following the purchase, the insider now directly owns 5,298,799 shares of the company’s stock, valued at $194,730,863.25. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Jose Carmona bought 3,000 shares of the business’s stock in a transaction dated Thursday, September 14th. The stock was acquired at an average price of $32.83 per share, for a total transaction of $98,490.00. Following the purchase, the chief financial officer now directly owns 3,000 shares in the company, valued at $98,490. The disclosure for this purchase can be found here. Insiders have acquired a total of 469,100 shares of company stock valued at $16,328,382 over the last three months. Corporate insiders own 15.00% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its stake in Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 541 shares during the last quarter. California State Teachers Retirement System lifted its stake in Radius Health by 6.1% in the second quarter. California State Teachers Retirement System now owns 65,950 shares of the biopharmaceutical company’s stock valued at $2,983,000 after purchasing an additional 3,780 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Radius Health by 17.3% in the second quarter. The Manufacturers Life Insurance Company now owns 27,677 shares of the biopharmaceutical company’s stock valued at $1,251,000 after purchasing an additional 4,083 shares during the last quarter. RA Capital Management LLC purchased a new position in Radius Health in the second quarter valued at approximately $22,486,000. Finally, State Street Corp lifted its stake in Radius Health by 12.9% in the second quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock valued at $84,473,000 after purchasing an additional 213,399 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “Radius Health, Inc. (RDUS) Receives Average Recommendation of “Hold” from Brokerages” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/11/radius-health-inc-rdus-receives-average-recommendation-of-hold-from-brokerages.html.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.